ClinicalTrials.gg
Active, not recruitingNCT03845166STELLAR-001Updated Nov 19, 2024

A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors

A Phase 1 interventional study of XL092 and Atezolizumab in Neoplasm Malignant, Renal Cell Carcinoma and Hormone Receptor Positive Breast Carcinoma, sponsored by Exelixis. Active, not recruiting at 86 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-19.

Sponsored by Exelixis · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
325
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a Phase 1, open-label, dose-escalation and expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect on biomarkers of XL092 administered alone, in combination with atezolizumab, and in combination with avelumab to subjects with advanced solid tumors.

02

Conditions studied

  • Neoplasm Malignant
  • Renal Cell Carcinoma
  • Hormone Receptor Positive Breast Carcinoma
  • Metastatic Castration-resistant Prostate Cancer
  • Colorectal Cancer
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 325 is above the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Exelixis is the lead sponsor of 57 studies on the registry; 11 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or histologically confirmed solid tumor that is inoperable locally advanced, , or recurrent.
  • Dose-escalation (single-agent and combination therapy): Subjects with a solid tumor that is unresectable or metastatic and for which life-prolonging therapies do not exist or available therapies are intolerable or no longer effective.
  • Expansion Cohort A (ccRCC): Subjects with previously treated advanced RCC with clear cell histology (including those with a sarcomatoid component) who have radiographically progressed following treatment with at least one prior systemic anticancer regimen for inoperable locally advanced or metastatic disease.
  • Expansion Cohorts B and E (nccRCC): Subjects with previously treated advanced RCC with non-clear cell histology who have radiographically progressed following treatment with at least one prior systemic anticancer regimen for inoperable locally advanced or metastatic disease.
  • Expansion Cohorts C and F (HR+ BC): Subjects with breast cancer that is hormone receptor positive (ER+ and/or PR+) and negative for human epidermal growth factor receptor 2 () and who have radiographically progressed during or following treatment with at least one prior systemic anticancer regimen for inoperable locally advanced or metastatic disease.
  • Expansion Cohorts D and G (mCRPC): Subjects with metastatic CRPC (adenocarcinoma of the prostate). Neuroendocrine differentiation and other features permitted if adenocarcinoma is the primary histology.
  • Expansion Cohort H (CRC): Subjects with histologically confirmed unresectable, locally advanced, or metastatic adenocarcinoma of the colon or rectum, KRAS/NRAS wild-type (confirmed via local testing report) and determined NOT to have microsatellite instability high (MSI-high) or mismatch repair deficient (dMMR) by local testing, who received the following standard of care chemotherapy regimens as prior therapy for metastatic CRC:

    • Fluoropyrimidine, irinotecan and oxaliplatin, with or without an anti-VEGF monoclonal antibody (bevacizumab)
    • Anti-EGFR monoclonal antibody (cetuximab or panitumumab)
    • BRAF inhibitor (in combination with cetuximab +/- binimetinib) for subjects with BRAF V600E mutations
  • Expansion Cohorts: Subjects must have per 1.1.
  • Tumor tissue material:

    • Subjects in the non-biomarker cohort provide archival, if available, or fresh tumor tissue if it can be safely obtained.
  • Recovery to baseline or ≤ Grade 1 severity ( v5) from adverse events (AEs), including immune-related adverse events (irAEs), related to any prior treatments, unless AE(s) are clinically nonsignificant and/or stable on supportive therapy.
  • (ECOG) Performance Status of 0-1.
  • Adequate organ and marrow function.
  • Sexually active fertile subjects and their partners must agree to use highly effective methods of .
  • Female subjects of must not be pregnant at screening.

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with XL092 (all cohorts), prior treatment with /PD-1 targeting immune checkpoint inhibitor (Cohorts E, F, G, and H only), or prior treatment with regorafenib and/or TAS-102 (Cohort H only).
  • Receipt of any type of small molecule kinase inhibitor within 2 weeks before first dose of study treatment.
  • Receipt of any type of anticancer antibody, systemic chemotherapy, or hormonal anticancer therapy within 4 weeks before first dose of study treatment.
  • Radiation therapy for bone within 2 weeks, any other radiation therapy within 4 weeks before first dose of study treatment. Subjects with ongoing complications from prior radiation therapy are not eligible.
  • Known or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 4 weeks before first dose of study treatment.
  • Uncontrolled, significant intercurrent or recent illness.
  • Concomitant use of certain medications.
  • interval calculated by the Fridericia formula (QTcF) > 450 ms for males and > 470 ms for females. Single ECGs are no longer permitted.
  • Pregnant or lactating females.
  • Diagnosis of another within 2 years before first dose of study treatment, except for superficial skin cancers, or localized, low grade tumors deemed cured and not treated with systemic therapy.

Additional Exclusion Criteria for XL092 + Atezolizumab Combination Therapy Cohorts ONLY:

  • Diagnosis of immunodeficiency or is receiving systemic therapy or any other form of therapy within 2 weeks prior to first dose of study treatment.
  • Administration of a live, attenuated vaccine within 30 days before first dose of study treatment.

Additional Exclusion Criteria for XL092 + Avelumab Combination Therapy Cohorts ONLY:

  • Active disease that might deteriorate when receiving an immunostimulatory agent.
  • Administration of a live, attenuated vaccine within 30 days before first dose of study treatment.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
325 participants (actual)

Study arms

  • Experimental
    XL092 Single-Agent Dose-Escalation Cohorts

    Subjects will accrue in cohorts of 3-6 subjects in a standard "3 plus 3" design.

    Drug: XL092

  • Experimental
    XL092 Single-Agent Expansion Cohorts

    The MTD or recommended dose from the dose-escalation stage may be further explored in clear cell renal cell carcinoma (ccRCC), non-clear cell renal cell carcinoma (nccRCC), hormone receptor-positive breast cancer (HR+ BC), and metastatic castration-resistant prostate cancer (mCRPC).

    Drug: XL092

  • Experimental
    XL092 + Atezolizumab Dose-Escalation Cohorts

    Subjects will accrue in cohorts of 2-6 subjects in a "rolling 6" design.

    Drug: XL092 · Drug: Atezolizumab

  • Experimental
    XL092 + Atezolizumab Expansion Cohorts

    The MTD or recommended dose from the dose-escalation stage may be further explored in non-clear cell renal cell carcinoma (nccRCC), hormone receptor-positive breast cancer (HR+ BC), metastatic castration-resistant prostate cancer (mCRPC), and colorectal cancer (CRC).

    Drug: XL092 · Drug: Atezolizumab

  • Experimental
    XL092 + Avelumab Dose-Escalation Cohorts

    Subjects will accrue in cohorts of 2-6 subjects in a "rolling 6" design.

    Drug: XL092 · Drug: Avelumab

Interventions

  • DrugXL092

    oral doses of XL092

  • Supplied as 1200 mg/20 mL vials; administered as a 1200 mg IV infusion once every 3 weeks (q3w)

    Also known as: Tecentriq®

  • Supplied as 200 mg/10 mL vials; administered as an 800 mg IV infusion once every 2 weeks (q2w)

    Also known as: Bavencio®

06

What researchers measure

Primary outcomes

  1. Dose-Escalation Stage: MTD/recommended dose for XL092

    To determine the maximum tolerated dose (MTD) and/or recommended dose (RD) for further evaluation of XL092 when administered alone and in combination with immune checkpoint inhibitors (ICIs) to subjects with advanced solid tumors

    Time frame: Up to 24 months

  2. Cohort-Expansion Stage: Objective Response Rate (ORR)

    To evaluate preliminary efficacy of XL092 when administered alone and in combination with ICIs by estimating ORR as assessed by the Investigator per RECIST 1.1

    Time frame: Up to 24 months

  3. Cohort-Expansion Stage (except Cohort H): Progression-Free Survival (PFS)

    To evaluate preliminary efficacy of single-agent XL092 and XL092 in combination with ICIs for specific cohorts by estimating the percentage of subjects with PFS at 6 months (PFS rate) per RECIST 1.1 as assessed by the Investigator (except for the CRC expansion cohort H)

    Time frame: Up to 24 months

  4. Cohort-Expansion Stage (Cohort H only): Overall Survival (OS)

    To evaluate preliminary efficacy of single-agent XL092 and XL092 in combination with atezolizumab for subjects with RAS wild-type CRC (Cohort H Treatment Arms H-A and H-B) by estimating overall survival (OS)

    Time frame: Up to 24 months

Secondary outcomes

  1. Incidence and Severity of Nonserious Adverse Events (AEs) and Serious Adverse Events (SAEs)

    To evaluate the safety of XL092 when administered alone and in combination with ICIs through the evaluation of incidence and severity of nonserious AEs and SAEs, including immune-related adverse events (irAEs), and adverse events of special interest (AESIs)

    Time frame: Up to 36 months

  2. Dose-Escalation Stage: Time to Maximum Plasma Concentration (Tmax)

    To evaluate the Tmax of XL092 alone and in combination with ICI

    Time frame: Up to 24 months

  3. Dose-Escalation Stage: Maximum Plasma Concentration (Cmax)

    To evaluate the Cmax of XL092 alone and in combination with ICI

    Time frame: Up to 24 months

  4. Dose-Escalation Stage: Area Under the Plasma Concentration-Time Curve Over the Last 24-hour Dosing Interval (AUC 0-24)

    To evaluate the AUC 0-24 of XL092 alone and in combination with ICI

    Time frame: Up to 24 months

  5. Dose-Escalation Stage: Terminal Half-Life

    To evaluate the terminal half-life of XL092 alone and in combination with ICI

    Time frame: Up to 24 months

  6. Dose-Escalation Stage: Apparent Clearance (CL/F)

    To evaluate the CL/F of XL092 alone and in combination with ICI

    Time frame: Up to 24 months

07

Study locations

86 sites
  • Exelixis Clinical Site #6
    Duarte, California 91010, United States
  • Exelixis Clinical Site #49
    La Jolla, California 92093, United States
  • Exelixis Clinical Site #7
    Los Angeles, California 90025, United States
  • Exelixis Clinical Site #84
    Los Angeles, California 90095, United States
  • Exelixis Clinical Site #66
    San Francisco, California 94158, United States
  • Exelixis Clinical Site #71
    Stanford, California 94305, United States
  • Exelixis Clinical Site #15
    Lake Mary, Florida 32746, United States
  • Exelixis Clinical Site #24
    Miami, Florida 33136, United States
  • Exelixis Clinical Site #11
    Atlanta, Georgia 30322, United States
  • Exelixis Clinical Site #80
    Atlanta, Georgia 30342, United States
  • Exelixis Clinical Site #41
    Iowa City, Iowa 52242, United States
  • Exelixis Clinical Site #36
    Westwood, Kansas 66205, United States
  • Exelixis Clinical Site #62
    Scarborough, Maine 04074, United States
  • Exelixis Clinical Site #44
    Baltimore, Maryland 21201, United States
  • Exelixis Clinical Site #4
    Boston, Massachusetts 02215, United States
  • Exelixis Clinical Site #45
    Ann Arbor, Michigan 48109, United States
  • Exelixis Clinical Site #2
    Grand Rapids, Michigan 49546, United States
  • Exelixis Clinical Site #25
    Saint Paul, Minnesota 55101, United States
  • Exelixis Clinical Site #13
    Omaha, Nebraska 68130, United States
  • Exelixis Clinical Site #9
    East Brunswick, New Jersey 08816, United States
  • Exelixis Clinical Site #83
    New Brunswick, New Jersey 08903, United States
  • Exelixis Clinical Site #85
    Bronx, New York 10461, United States
  • Exelixis Clinical Site #86
    New York, New York 10021, United States
  • Exelixis Clinical Site #35
    New York, New York 10029, United States
  • Exelixis Clinical #78
    New York, New York 10065, United States
  • Exelixis Clinical #74
    Cincinnati, Ohio 45219, United States
  • Exelixis Clinical Site #60
    Cleveland, Ohio 44106, United States
  • Exelixis Clinical Site #59
    Hershey, Pennsylvania 17033, United States
  • Exelixis Clinical Site #58
    Philadelphia, Pennsylvania 19107, United States
  • Exelixis Clinical Site #12
    Pittsburgh, Pennsylvania 15232, United States
  • Exelixis Clinical Site #61
    Charleston, South Carolina 29425, United States
  • Exelixis Clinical Site #50
    Myrtle Beach, South Carolina 29572, United States
  • Exelixis Clinical Site #33
    Germantown, Tennessee 38138, United States
  • Exelixis Clinical Site #87
    Nashville, Tennessee 37203, United States
  • Exelixis Clinical Site #3
    Houston, Texas 77030, United States
  • Exelixis Clinical Site #1
    San Antonio, Texas 78229, United States
  • Exelixis Clinical Site #5
    Salt Lake City, Utah 84112, United States
  • Exelixis Clinical Site #8
    Charlottesville, Virginia 22903, United States
  • Exelixis Clinical Site #43
    Richmond, Virginia 23219, United States
  • Exelixis Clinical Site #26
    Spokane, Washington 99208, United States
  • Exelixis Clinical Site #52
    Darlinghurst, New South Wales 2010, Australia
  • Exelixis Clinical Site #53
    Liverpool, New South Wales 2170, Australia
  • Exelixis Clinical #75
    South Brisbane, Queensland 4101, Australia
  • Exelixis Clinical Site #56
    Kurralta Park, South Australia 5037, Australia
  • Exelixis Clinical Site #63
    Heidelberg, Victoria 3084, Australia
  • Exelixis Clinical Site #44
    Edegem, Antwerpen 2650, Belgium
  • Exelixis Clinical Site #65
    Gent, Oost-Vlaanderen 9000, Belgium
  • Exelixis Clinical Site #51
    Brussels, 1200, Belgium
  • Exelixis Clinical Site #21
    Brno, 656 91, Czechia
  • Exelixis Clinical Site #42
    Hradec Králové, 500 05, Czechia
  • Exelixis Clinical Site #10
    Olomouc, 779 00, Czechia
  • Exelixis Clinical Site #27
    Praha, 140 59, Czechia
  • Exelixis Clinical Site #46
    Clermont, Ferrand 63011, France
  • Exelixis Clinical Site #37
    Saint-Herblain Cedex, Loire Atlantique 44805, France
  • Exelixis Clinical #72
    Bordeaux, 33000, France
  • Exelixis Clinical Site #32
    Caen Cedex 5, 14076, France
  • Exelixis Clinical Site #48
    Marseille, 13009, France
  • Exelixis Clinical Site #14
    Paris, 75015, France
  • Exelixis Clinical Site #39
    Pierre-Bénite, 69495, France
  • Exelixis Clinical Site #47
    Poitiers, 86021, France
  • Exelixis Clinical Site #22
    Suresnes, 92150, France
  • Exelixis Clinical Site #57
    Toulouse Cedex 9, 31059, France
  • Exelixis Clinical #77
    Villejuif, 94805, France
  • Exelixis Clinical Site #38
    Nürtingen, Baden-Wuerttemberg 72622, Germany
  • Exelixis Clinical Site #31
    Münster, Nordrhein-Westfalen 48149, Germany
  • Exelixis Clinical Site #64
    Hamburg, 20249, Germany
  • Exelixis Clinical Site #67
    Milan, MI 20132, Italy
  • Exelixis Clinical Site #69
    Pavia, PV 27100, Italy
  • Exelixis Clinical Site #54
    Milan, 20141, Italy
  • Exelixis Clinical #73
    Napoli, 80131, Italy
  • Exelixis Clinical Site #79
    Amsterdam, Noord-Holland 1066 CX, Netherlands
  • Exelixis Clinical #76
    Rotterdam, South Holland 3015 GD, Netherlands
  • Exelixis Clinical Site #23
    Sabadell, Barcelona 08208, Spain
  • Exelixis Clinical Site #20
    Santiago De Compostela, La Coruna 15706, Spain
  • Exelixis Clinical Site #18
    Barcelona, 08003, Spain
  • Exelixis Clinical Site #19
    Barcelona, 08023, Spain
  • Exelixis Clinical Site #29
    Barcelona, 08035, Spain
  • Exelixis Clinical Site #30
    Barcelona, 08036, Spain
  • Exelixis Clinical Site #81
    Madrid, 28007, Spain
  • Exelixis Clinical Site #34
    Madrid, 28040, Spain
  • Exelixis Clinical Site #55
    Madrid, 28041, Spain
  • Exelixis Clinical Site #17
    Madrid, 28046, Spain
  • Exelixis Clinical Site #16
    Sevilla, 41013, Spain
  • Exelixis Clinical #70
    London, England W1G6AD, United Kingdom
  • Exelixis Clinical Site #40
    Sutton, England SM2 5PT, United Kingdom
  • Exelixis Clinical Site #68
    Preston, Lancashire PR29HT, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2019 (actual). Primary completion is estimated for Aug 2026, 89 months after the start.

Of 677 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 62. This study's planned 89 months is above that.

Counting every sponsor, half of 904 studies reached it within 40 months; a quarter within 23 and three quarters within 64.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 15, 2019
First posted
Feb 19, 2019
StartActual
Mar 20, 2019
Primary completionEst.
Aug 31, 2026
CompletionEst.
May 31, 2027
Last update
Nov 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03845166
Lead sponsor
Exelixis
Responsible party
Sponsor
First posted
Feb 19, 2019
Start date
Mar 20, 2019
Primary completion
Aug 31, 2026 (estimated)
Completion
May 31, 2027 (estimated)
Last update
Nov 19, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zanzalintinib

Start the discussion